



น.พ.เจริญ ชูโชติถาวร ผู้ทรงคุณวุฒิ สถาบันโรคทรวงอก กรมการแพทย์



- Respiratory tract infection is very common in HIV infected patients.
- Viral infection of upper respiratory tract and bacterial infection of lower respiratory tract are very common.
- Because of immunocompromised condition of HIV infected patients, certain specific organisms which need CMI protection is increasing incidence such as mycobacteria, fungus, etc.



Respiratory tract infections in HIV/AIDS patients

Upper Respiratory Tract

- * Rhinitis
- * Pharyngitis
- Sinusitis (chronic cough)

Lower Respiratory Tract


Usual diseases

Bronchitis

Bronchiectasis


Pneumonia

Tuberculosis



Unusual diseases


- * Pneumocystis jirovecii pneumonia
- Nocardiosis
- * Rhodococcosis
- * Cryptococcosis
- * Histoplasmosis
- Salmonellosis
- * Aspergillosis
- * Cytomegalovirus




Pulmonary

Non Infectious Diseases in HIV/AIDS Patients

- Kaposi sarcoma involved lung
- Lymphoid interstitial pneumonia (LIP)
- * Non specific interstitial pneumonia






This is an acid fast stain of Mycobacterium tuberculosis (MTB).

Note the red rods - hence the terminology for MTB in histological sections or smears: acid fast bacilli.

เชื้อวัณโรค

- เป็นเชื้อแบคทีเรีย มาใช่ไวรัส
- เชื้อวัณโรค ไม่สร้างสารพิษ ทำให้เมื่อมีการ
 ติดเชื้อ จะไม่มีอาการ
- เชื้อวัณโรคไม่ทนความแห้งแล้ง และ อุณหภูมิที่สูง
- เชื้อวัณโรคจะก่อโรคได้เมื่อหายใจเข้าไปใน ปอด ไม่ติดต่อดดยการสัมผัส หรือ รับประทาน
- เชื้อวัณโรค ก่อโรคที่ปอดบ่อยที่สุด แต่ก่อ โรคในอวัยวะอื่นนอกปอดได้





A : TB, no risk HIV

: Rx TB, control HIV spreading

B : TB ,risk HIV

: VCT, Rx TB

C: TB, HIV positive


: Rx TB, ARVT


D : T.T. positive , HIV positive


: Prophylaxis, ARVT

E : T.T. negative ,HIV positive

: ARVT, active surveillance TB








ความสำคัญของวัณโรคในผู้ป่วยที่มีการติดเชื้อโรคไวรัสโรคเอดส์


- เป็นโรคติดต่อที่พบบ่อยที่สุดในผู้ที่ติดเชื้อไวรัสโรคเอดส์
- เป็นโรคติดต่อที่สามารถติดต่อมาที่บุคคลากรได้ง่ายจากการพูดคุย ไอ จาม
- ผู้ป่วยวัณโรคที่มีการติดเชื้อไวรัสโรคเอดส์ร่วมด้วยจะมี ลักษณะของวัณโรคแปลกๆ ทำให้วินิจฉัยยาก
- ผู้ป่วยวัณโรคที่มีการติดเชื้อไวรัสโรคเอดธ์ร่วมด้วยจะมี ภูมิต้านทานแย่ลงเร็วกว่าไม่มีวัณโรค
- ผู้ป่วยวัณโรคที่มีการติดเชื้อไวรัสโรคเอดส์ร่วมด้วยจะมี อัตราการดื้อยารักษาวัณโรคสูง
- ผู้ป่วยวัณโรคที่มีการติดเชื้อไวรัสโรคเอดส์ร่วมด้วยจะมี การแพ้ยาวัณโรคได้มากกว่าวัณโรคธรรมดา
- ผู้ป่วยวัณโรคที่มีการติดเชื้อไวรัสโรคเอดส์ร่วมด้วยจะมี การเสียชีวิตหลังการรักษาวัณโรคมากกว่า

การป้องกันไม่ให้ป่วยเป็นวัณโรค จะเป็นวิธีที่ดีที่สุด




CLINICAL FEATURES OF TB IN HIV SEROPOSITIVE PATIENTS

	Early	Late
	(less immune deficiency)	(advanced immune deficiency)
Signs/Symptoms	- Fever, weight loss are	- Stigma of AIDS
	prominent	
	- Extrapulmonary lesion	- more extrapulmonary
Chest X - ray	- Apical disease with cavitation	- more Atypical disease
	- Adenopathy	- hilar adenopathy, lower lobe
		lesion, miliary, interstitial,
		pleural, normal
Tuberculin test	- Positive 80%	- Positive < 80%
Bacteriology	- less positive	- Less positive
	- Mycobacteremia	- Mycobacteremia is common



YIELDS OF	MICROSCOPIC	SPUTUM	EXZMINATION	IN	HIV
INFECTED	TUBERCULOSIS	PATIENT	S		

	HIV positive	HIV negative		
	(%posi	(%positive smear)		
Pitchenik 1987	36	35		
Modilevsky 19	89 83	-		
Klein 1989	45	81		
Thuer 1990	47	51		
Long 1991	64	78		
Nunn 1992	71	83		



CORRELATION BETWEEN CD₄ T- LYMPHOCYTE AND SPUTUM SMEAR RESULT IN HIV POSITIVE PATIENTS

	CD ₄ cell count (cell/ l)			
	0 - 100	101 - 200	201 - 300	> 300
Jones, 1992	70%	85%	50%	56%
Smith, 1994	58%	60%	56%	-
Karstaedt 1998	76%	59%	36%	67%



Detection of LAM antigen in Urine for Diagnosis of

Tuberculosis

Bar Fleight J 2011; 30: 1306-1405 00:181183/8983/998.8082571 Drawnighto ERS 2811



Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis

J. Minion***, E. Leung**, E. Talbot', K. Dheda', M. Pai** and D. Menzies**

ABSTRACT: Lipparabinomannan (LAM) is a potential marker of active tuberculosis (TB). We | AFFURTION performed a systematic review and meta-analysis regarding use of urinary LAM assays for diagnosing active TB.

We systematically searched for published and unpublished studies that evaluated urinary LAM for active TB diagnosis. Extracted data were pooled using bivariate random effects models and hierarchical summary receiver operating characteristic curves. Heterogeneity was explored through subgroup analysis and meta-regression. Quality was assessed according to standardised QUADAS (Quality Assessment of Diagnostic Accuracy Studies) criteria.

In seven studies that assessed test accuracy in microbiologically confirmed cases only, estimates of sensitivity ranged from 13% to 93%, while specificity ranged from 87% to 99%. In five studies that assessed accuracy in clinical and confirmed TB cases, sensitivity ranged from \$% to 80%, while specificity ranged from 88% to 99%. In five studies with results stratified by HIV status, sensitivity was 3-53% higher in HIV-positive than HIV-negative subgroups; sensitivity was highest with advanced immunosuppression.

The LAM urinary assay has several characteristics that make it attractive for diagnosing active TB, but has suboptimal sensitivity for routine clinical use. Further studies are needed to evaluate the potential value of the LAM assay in individuals with advanced HIV or for diagnosis of paediatric TB.

'Digit of Epidemiology, Diesafotos and Occupational Health, McGill. *Yaqqiratony Eolosmiology and


Chrisial Presserch Unit, Montreal Chest tredicts, Manteux, GC. *Gost of Medical Efficiencyclose and: Irom,mology, University of Alberta.

Edmorton, Alt. Carada. Foundation for theoretive time Discrepto IPMDs Govern. Switzwitzet.

Division of Polyneman and Chical Instrumingly, Dept of Mediums, University of Cape Yows, Cape Town.

CONSUPRADING

Record Rt 29 Montaul Chest Indians 3659 St Urbain Short



Detection of LAM antigen in Urine for

Diagnosis of Tuberculosis


TABLE 3	Summary of data comparing diagnostic a in groups stratified by CD4 count in HIV co tuberculosis (TB) suspects		
First author [ref.]	CD4 count cells·mm ⁻³	Sensitivity (95% CI) %	Specificity (95% CI) %
Lawn [22]#	<50	67 (41-87)	100 (94-100)
	50-100	35 (14-62)	100 (94-100)
	>100	4 (0-22)	100 (94-100)
DHEDA [25] ¹	<200	37 (16-62)	100 (81-100)
	≥200	0 (0-18)	100 (17-100)
SHAH [26]*	<50	85 (73-93)	NA
	50-100	71 (51-87)	NA
	101-150	56 (30-80)	NA:
	>150	51 (38-64)	NA




CONVERSION OF SPUTUM TEST TO NEGATIVE DURING SIX MONTHS OF CHEMOTHERAPY FOR TUBERCULOSIS

	HIV positive (%)	HIV negative (%)
Microscopy after		
2 months	87.6	88.5
4 months	99.2	98.9
6 months	99.2	98.9
Culture after		
2 months	98.2	93.3
6 months	92.9	92.1











TREATMENT OF HIV SEROPOSITIVE TUBERCULOSIS PATIENTS


- * Same regimen as HIV seronegative patients
- * Standard 2HRZE/4HR
- * Directly observed therapy (DOT)





























PARADOXICAL TUBERCULOUS REACTION

- Transient worsening of disease at a preexisting site or developing of new tuberculosis lesions following initiation of appropriate treatment
- Interaction between host immune response and mycobacteria product (or other organisms)
- In HIV infected tuberculosis patients, the reaction is associated with ARV treatment




"Paradoxical IRIS"

OIs treatment--> start HAART --> clinical worsening


"Unmasking IRIS "

Start HAART --> develop OIs with atypical manifestation




Entities to Exclude When Considering Paradoxical Reactions

- Drug non-compliance
- Acquired drug resistance
- Malabsorption of antituberculosis drugs
- Concurrent opportunistic infection
- Malignancy
- · Drug reaction



CD4 CELL COUNT AT TB DIAGNOSIS : CASE CONTROL STUDY (Punnotok J, IJTLD, 2000)

CD4 cell count	HIV positive	HIV negative
>500	10%	69%
200-499	31%	31%
<200	55%	0%







CAPRISA IS A UNAIDS COLLABORATING CENTRE OR HIV PREVENTION RESEARCH

Addressing challenges in treating TB-HIV co-infected patients

The SAPiT Trial: Starting Antiretroviral therapy at three Points in TB

Dr Kogie Naidoo

Presented at the

3rd ANNUAL WORKSHOP ON ADVANCED CLINICAL CARE (AWACC) – AIDS, DURBAN 2009, 1 October 2009


On behalf of :



Salim Abdool Karim, Anneke Grobler, Nesri Padayatchi, Andrew Gray, Jacqueline Pienaar, Tanuja Gengiah, Gonasagrie Nair, Sheila Bamber, Aarthi Singh, Munira Khan, Wafaa El-Sadr, Gerald Friedland and Quarraisha Abdool Karim











TB patient who is co-infected with HIV should

- Start treatment with anti-TB first
- Co-trimoxazole prophylaxis should be started concomitantly for prevention of PJP
- Anti-retroviral therapy should be started not later than 8 weeks after commencing anti-TB drugs



HIV infected patient

- TB has to be excluded.
- Subclinical opportunistic infections have to be excluded as well.
- INH prophylaxis is recommended but there was a controversy in Thailand because
 - Poor compliance of patient
 - High prevalence of INH resistance
 - Afraid to induce INH resistance



"Think TB - Think HIV"

"Think HIV - Think TB"